Delivery Order SPE2DB22D3301-SPE2DB25FZ1GE
Award Date 9/19/25
Potential Completion Date 9/22/25
Potential Value $3.7K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded a $8,787.92 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pens on May 12, 2025, with completion expected by May 13, 2025. This firm fixed-price delivery order represents a non-competitive award under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion pharmaceutical prime vendor vehicle running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a delivery order valued at $6,977.88 to AmerisourceBergen Drug Corp for ZEPBOUND 10 mg/0.5 ml pen auto-injectors on September 8, 2025, with an ultimate completion date of September 9, 2025. This firm fixed price, non-competitive delivery order will be fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. ZEPBOUND is a semaglutide-based medication used for weight management in adults with obesity or overweight conditions,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections valued at $1,143.87 on July 21, 2025, with an ultimate completion date of July 22, 2025. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections valued at $13,477.84. This firm fixed-price delivery order, which represents a child contract under a larger indefinite delivery vehicle, will be fulfilled from the vendor's location in Conshohocken, Pennsylvania, with an ultimate completion date of September 9, 2025. The award was made on a competitive basis with no...
- The Defense Logistics Agency awarded a $13,994.32 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on August 25, 2025, with ultimate completion by August 26, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of performance...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections on April 24, 2025, with a contract ceiling value of $8,646.13 and ultimate completion date of April 25, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December...
- The Defense Logistics Agency awarded a $3,431.65 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 12.5 mg/0.5 mL pens on August 1, 2025, with completion targeted for August 4, 2025. This non-competitive delivery order was issued under an existing contract vehicle and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist indicated for weight management, reflecting the...
- The Defense Logistics Agency awarded a delivery order valued at $20,839.40 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on August 12, 2025, with completion scheduled for August 13, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, which serves as the company's corporate...
- The Defense Logistics Agency awarded a $25,072.55 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pens on a firm fixed price basis. The contract, which was competitively awarded without set-aside designation, has an ultimate completion date of September 12, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. Zepbound is a GLP-1 receptor agonist medication primarily used for weight...
- The Defense Logistics Agency awarded a $4,809.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 2.5 mg/0.5 mL pens on August 19, 2025, with an ultimate completion date of August 20, 2025. This is an unset-aside, competitively awarded contract utilizing the company's existing Indefinite Delivery Contract vehicle with DLA. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's...